Growth Metrics

Acro Biomedical (ACBM) Non-Current Debt (2021 - 2022)

Acro Biomedical's quarterly Non-Current Debt came in at $78826.0 in Q4 2022, up 280.05% year-on-year from $20741.0 in Q4 2021, and up 280.05% quarter-over-quarter from $20741.0 in Q4 2021.

Acro Biomedical has reported Non-Current Debt for 2 years, with the latest figure at $78826.0 in Q4 2022.

  • For the quarter ending Q4 2022, Non-Current Debt rose 280.05% year-over-year to $78826.0; the trailing twelve-month figure through Dec 2022 stood at $78826.0 (up 280.05% YoY), and the FY2022 full-year result was $78826.0, up 280.05% from the prior year.
  • Non-Current Debt for Q4 2022 stood at $78826.0, up from $20741.0 in the prior quarter.
  • The five-year high for Non-Current Debt was $78826.0 in Q4 2022, with the low at $20741.0 in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 EQV Ventures Acquisition 477.69 Mn 477.69 Mn - -
2 Berto Acquisition 316.66 Mn 316.66 Mn - -
3 Centurion Acquisition 311.94 Mn 311.94 Mn - -
4 Churchill Capital Corp IX 311.36 Mn 311.36 Mn - -
5 Agriculture & Natural Solutions Acquisition 301.94 Mn 301.94 Mn - -
6 Siddhi Acquisition Corp (Cayman Islands) 286.76 Mn 286.76 Mn - -
7 Bold Eagle Acquisition 276.06 Mn 276.06 Mn - 542,975.00
8 Cartesian Growth Corp III 270.68 Mn 270.68 Mn - -
9 Oyster Enterprises II Acquisition 266.84 Mn 266.84 Mn - -
10 Acro Biomedical - - - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 78,826.00
Dec 31, 2022 78,826.00
Dec 31, 2021 20,741.00
Dec 31, 2021 20,741.00